SOHO Italy 2022 | An insight into MRD monitoring and MRD-driven treatment in AML
Francesco Buccisano
• 24 Oct 2022
Francesco Buccisano, MD, University of Rome Tor Vergata, Rome, Italy, discusses measurable residual disease (MRD) monitoring and driven treatment in acute myeloid leukemia (AML), considering both flow cytometry and RT-qPCR, and further highlights the value of using MRD as a tool to evaluate the chemo-sensitivity of disease. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
